Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.

Literature DB >> 14693563

In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.

Chiu-Yeung Chan¹, Carrie Au-Yeang, Wing-Wai Yew, Chi-Chiu Leung, Augustine F B Cheng.

Abstract

Postantibiotic effects (PAEs) of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis ATCC 27294 were studied using a radiometric culture system. Rifapentine at 20 mg/liter gave the longest PAE (104 h) among the drugs used alone. The combinations of rifapentine plus isoniazid, rifapentine plus moxifloxacin, and isoniazid plus moxifloxacin gave PAEs of 136.5, 59.0, and 8.3 h, respectively.

Entities: Chemical Species

Mesh：

Substances：

Year: 2004 PMID： 14693563 PMCID： PMC310201 DOI： 10.1128/AAC.48.1.340-343.2004

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

24 in total

1. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.

Authors: Yanmin Hu; Anthony R M Coates; Denis A Mitchison
Journal: Antimicrob Agents Chemother Date: 2003-02 Impact factor: 5.191

2. In vitro and in vivo studies to assess the suitability of antituberculous drugs for use in intermittent chemotherapy regimens.

Authors: J M Dickinson; D A Mitchison
Journal: Tubercle Date: 1968-03

3. Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis.

Authors: J M Dickinson; G A Ellard; D A Mitchison
Journal: Tubercle Date: 1968-12

4. Postantibiotic effects.

Authors: B S Vogelman; W A Craig
Journal: J Antimicrob Chemother Date: 1985-01 Impact factor: 5.790

5. Postantibiotic suppression of bacterial growth.

Authors: R W Bundtzen; A U Gerber; D L Cohn; W A Craig
Journal: Rev Infect Dis Date: 1981 Jan-Feb

Review 6. Whither short-course chemotherapy?

Authors: W Fox
Journal: Br J Dis Chest Date: 1981-10

7. Suitability of rifampicin for intermittent administration in the treatment of tuberculosis.

Authors: J M Dickinson; D A Mitchison
Journal: Tubercle Date: 1970-03

8. Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis.

Authors: J M Dickinson; D A Mitchison
Journal: Tubercle Date: 1970-12

9. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces.

Authors: Olaf Burkhardt; Klaus Borner; Heino Stass; Gerrit Beyer; Markus Allewelt; Carl Erik Nord; Hartmut Lode
Journal: Scand J Infect Dis Date: 2002

10. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods.

Authors: C B Inderlied; L S Young; J K Yamada
Journal: Antimicrob Agents Chemother Date: 1987-11 Impact factor: 5.191

13 in total

1. In vitro antimycobacterial activities of capuramycin analogues.

Authors: Venkata M Reddy; Leo Einck; Carol A Nacy
Journal: Antimicrob Agents Chemother Date: 2007-12-10 Impact factor: 5.191

Review 2. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors: Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal: Antimicrob Agents Chemother Date: 2008-12-15 Impact factor: 5.191

3. A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors: John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal: Pharm Res Date: 2013-11-16 Impact factor: 4.200

4. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.

Authors: Venkata M Reddy; Leo Einck; K Andries; Carol A Nacy
Journal: Antimicrob Agents Chemother Date: 2010-04-12 Impact factor: 5.191

5. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.

Authors: Radha K Shandil; Ramesh Jayaram; Parvinder Kaur; Sheshagiri Gaonkar; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; V Balasubramanian
Journal: Antimicrob Agents Chemother Date: 2006-12-04 Impact factor: 5.191

6. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models.

Authors: Zahoor Ahmad; Mostafa M Fraig; Michael L Pinn; Sandeep Tyagi; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal: J Antimicrob Chemother Date: 2011-05-20 Impact factor: 5.790

Review 7. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.

Authors: Pavan K Vaddady; Richard E Lee; Bernd Meibohm
Journal: Future Med Chem Date: 2010-08 Impact factor: 3.808

8. Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system.

Authors: Amy Sarah Ginsburg; Jin Lee; Samuel C Woolwine; Jacques H Grosset; Fayez M Hamzeh; William R Bishai
Journal: Antimicrob Agents Chemother Date: 2005-02 Impact factor: 5.191

Review 9. A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

Authors: Anushka Naidoo; Kogieleum Naidoo; Helen McIlleron; Sabiha Essack; Nesri Padayatchi
Journal: J Clin Pharmacol Date: 2017-07-24 Impact factor: 3.126

10. Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis.

Authors: Santosh Wagh; Chetan Rathi; Pradeep B Lukka; Keyur Parmar; Zaid Temrikar; Jiuyu Liu; Michael S Scherman; Richard E Lee; Gregory T Robertson; Anne J Lenaerts; Bernd Meibohm
Journal: Antimicrob Agents Chemother Date: 2021-08-23 Impact factor: 5.191